3D Photoacoustic Tomography (PAT)and Dynamic Contrast-Enhanced PAT Breast Imaging

描述（由申请人提供）：在与教师和工作人员在医学院的合作，OptoSonics提出开发和验证一种新的临床成像平台，乳腺癌筛查的患者人群的X射线乳腺摄影是不太敏感。该平台将允许临床医生评估乳腺癌的两种不同生物标志物-可疑肿块内的血红蛋白分布和血流-在致密乳腺妇女，50岁以下妇女以及具有遗传或家族易感性的乳腺癌妇女中。两种新的成像技术将集成到一个平台中：用于光学吸收成像的3D光声计算机断层扫描（PAT）;以及用于量化可疑肿块中血流和灌注的动态对比增强PAT（DCE-PAT）。两种模式将在空间上共同配准，因为它们共享适形探测器几何结构。我们的目标是证明1.0毫米的空间分辨率成像血红蛋白在整个乳房，对胸壁压缩到< 5厘米，并量化血流可疑肿块内的空间分辨率为0.5毫米。这种新的成像技术的临床效用将通过几个临床研究进行评估。

DESCRIPTION (provided by applicant): In collaboration with faculty and staff at the UNC School of Medicine, OptoSonics proposes to develop and validate a new clinical imaging platform for breast cancer screening in patient populations for whom X-ray mammography is less sensitive. This platform will allow clinicians to assess two distinct biomarkers of breast cancer - hemoglobin distribution and blood flow within suspicious masses - in women with dense breast, women < 50 years of age, and those with a genetic or familial predisposition to breast cancer. Two new imaging technologies will be integrated into a single platform: 3D photoacoustic computed tomography (PAT) for imaging optical absorption; and, Dynamic, contrast-enhanced PAT (DCE-PAT) for quantifying blood flow and perfusion in suspicious masses. Both modalities will be co-registered spatially as they share conformal detector geometries. Our goal is to demonstrate 1.0 millimeter spatial resolution for imaging hemoglobin throughout the whole breast, compressed against the chest wall to < 5 cm, and to quantify blood flow within suspicious masses with spatial resolution 0.5 mm. The clinical utility of this new imaging technology will be evaluated through several, clinical studies.